Of the respondents, 438 reported having received Cysview and said they were diagnosed at one facility, but then went to another that offers Blue Light Cystoscopy (BLC™) with Cysview.1
Cysview is an optical imaging agent that when viewed in blue light makes bladder cancer tumors glow bright pink. When lesions are easier to see, they are easier to remove. A Blue Light Cystoscopy with Cysview is performed as an adjunct to standard White Light Cystoscopy. The additional step of switching to blue light helps urologists be more confident that they are performing a more complete TURBT or more thorough surveillance.2,3 Better detection may lead to appropriate risk categorization and improved patient management outcomes.4
Bladder cancer patients report high interest in and satisfaction with Cysview (2019): 1
- 87.45% received BLC with Cysview
- 99.32% said it helped in managing their cancer
- 99.55% reported improved confidence in the treatment they received
- 99.77% confirmed the importance of having BLC with Cysview as part of their disease management
For four years, Photocure Inc. has worked with BCAN to implement this annual survey. Over that time, perception and opinion of Cysview have improved steadily each year, as have patient experiences and confidence in their treatment.
The 2016 AUA/SUO NMIBC Guideline includes Blue Light Cystoscopy with Cysview:1
- #30. In a patient with NMIBC, a clinician should offer blue light cystoscopy at the time of TURBT, if available, to increase detection and decrease recurrence. (Moderate Recommendation; Evidence Strength: Grade B)
Important Safety Information About Cysview® (hexaminolevulinate HCl)
Cysview is not a replacement for random bladder biopsies or other procedures used in the detection of bladder cancer.
Anaphylactoid shock, hypersensitivity reactions, bladder pain, cystitis, and abnormal urinalysis have been reported after administration of Cysview. The most common adverse reactions seen in clinical trials were bladder spasm, dysuria, hematuria, and bladder pain.
Cysview should not be used in patients with porphyria, gross hematuria, or with known hypersensitivity to hexaminolevulinate or any derivative of aminolevulinic acid. Cysview may fail to detect some malignant lesions. False-positive fluorescence may occur due to inflammation, cystoscopic trauma, scar tissue, previous bladder biopsy and recent BCG therapy or intravesical chemotherapy. No specific drug interaction studies have been performed.
Safety and effectiveness have not been established in pediatric patients. There are no available data on Cysview use in pregnant women. Adequate reproductive and developmental toxicity studies in animals have not been performed. Systemic absorption following administration of Cysview is expected to be minimal. There are no data on the presence of hexaminolevulinate in human or animal milk, the effects on a breastfed infant, or the effects on milk production. The development and health benefits of breastfeeding should be considered along with the mother’s clinical need for Cysview and any potential adverse effects on the breastfed infant from Cysview or from the underlying maternal condition.
Cysview is approved for use with the KARL STORZ D-Light C Photodynamic Diagnostic (PDD) system. For system set-up and general information for the safe use of the PDD system, please refer to the KARL STORZ instruction manuals for each of the components.
- For more information about the impact of Cysview on the diagnosis and management of bladder cancer, visit Cysview.com.
- Prior to Cysview administration, read the Full Prescribing Information and follow the preparation and reconstitution instructions
- Cysview is currently available in more than 150 facilities throughout the United States, with more sites being added regularly.
1. Survey of self-selected patients completed through the Bladder Cancer Advocacy Network (BCAN) sponsored by Photocure, Jan. 2016 n=222, Jan. 2017 n=568, Jan. 2018 n=550, Jan. 2019 n=600.
2. Babjuk M, Soukup V, et al. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 2005;96:798-802.
3. Daneshmand S et al. Efficacy and safety of blue light flexible cystoscopy With Hexaminolevulinate (HAL) in the surveillance of bladder cancer: A phase III, comparative, multi-center study. J Urol. 2017 Dec 2. pii: S0022-5347(17)78004-4. doi: 10.1016/j.juro.2017.11.096. [Epub 2017 Dec 2].
4. Cumberbatch MGK, Foerster B, Catto JWF, et al. Repeat transurethral resection in non-muscle-invasive bladder cancer: a systematic review. Eur Urol. 2018;73(6):925-933.
5. American Urological Association. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. American Urological Association. 2016.
Further Related Content:
Watch: Blue Light Cystoscopy with Cysview® in the Surveillance of Bladder Cancer - Sia Daneshmand